An 8-Week Double-Blind, Multicenter, Randomized, Multifactorial, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension.

Trial Profile

An 8-Week Double-Blind, Multicenter, Randomized, Multifactorial, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Aliskiren; Amlodipine
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 16 Oct 2010 Actual end date changed from Jun 2009 to May 2009 as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Actual patient number (1688) added as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top